Ken Griffin Bio N Tech Se Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio N Tech Se stock. As of the latest transaction made, Citadel Advisors LLC holds 126,000 shares of BNTX stock, worth $10.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,000
Previous 218,100
42.23%
Holding current value
$10.6 Million
Previous $23 Million
49.5%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BNTX
# of Institutions
326Shares Held
40.4MCall Options Held
1.31MPut Options Held
1.37M-
Baillie Gifford & CO8.36MShares$705 Million0.61% of portfolio
-
Primecap Management CO Pasadena, CA4.81MShares$406 Million0.34% of portfolio
-
Harding Loevner LP Bridgewater, NJ3.82MShares$322 Million2.24% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M3.47MShares$293 Million1.4% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U03.43MShares$289 Million1.76% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $20.5B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...